

1 **Diminishing immune responses against variants of concern in dialysis**
2 **patients four months after SARS-CoV-2 mRNA vaccination**

3

4 Alex Dulovic^{a,#}, Monika Strengert^{b,c,#}, Gema Morillas Ramos^{d,#}, Matthias Becker^a, Johanna
5 Griesbaum^a, Daniel Junker^a, Karsten Lürken^e, Andrea Beigel^e, Eike Wrenger^e, Gerhard Lonnemann^e,
6 Anne Cossmann^d, Metodi V. Stankov^d, Alexandra Dopfer-Jablonka^{d,f}, Philipp D. Kaiser^a, Bjoern
7 Traenkle^a, Ulrich Rothbauer^{a,g}, Gérard Krause^{b,c,§,*}, Nicole Schneiderhan-Marra^{a,§,*}, Georg M.N.
8 Behrens^{d,f,h,§,*}

9

10 Author Affiliations

11 a NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

12 b Helmholtz Centre for Infection Research, Braunschweig, Germany

13 c TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the
14 Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

15 d Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany

16 e Dialysis Centre Eickenhof, Langenhagen, Germany

17 f German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

18 g Pharmaceutical Biotechnology, University of Tübingen, Germany

19 h CiiM - Centre for Individualized Infection Medicine, Hannover, Germany

20 #, § these authors contributed equally to this work.

21 * corresponding authors.

22

23 **Abstract**

24 Patients undergoing chronic hemodialysis were among the first to receive SARS-CoV-2 vaccinations
25 due to their increased risk for severe COVID-19 disease and high case fatality rates. To date, there
26 have been minimal longitudinal studies in hemodialysis patients to ascertain whether protection
27 offered by vaccination is long-lasting. To assess how surrogates for protection changed over time, we
28 examined both the humoral and cellular response in a previously reported cohort of at-risk
29 hemodialysis patients and healthy donors, four months after their second dose of Pfizer BNT162b2.
30 Compared to three weeks post-second vaccination, both cellular and humoral responses against the
31 original SARS-CoV-2 isolate as well as variants of concern were significantly reduced, with some
32 dialyzed individuals having no B- or T-cell response. Our data strongly support the need for a third
33 booster in hemodialysis patients and potentially other at-risk individuals.

34 **Main**

35 Persistence of vaccination-induced cellular and humoral immune responses is crucial to prevent
36 SARS-CoV-2 infection or at least provide protection against severe COVID-19 requiring
37 hospitalization. As in many other countries, the SARS-CoV-2 vaccination strategy in Germany was
38 based on prioritization by occupation, underlying medical conditions or advanced age¹. While those
39 priority groups have been vaccinated, a debate has emerged as to whether a third “booster” dose may
40 be necessary to maintain or raise levels of protection within some of these groups. Decisions on
41 whether to recommend a third dose should be made within a short time frame, as it is expected that
42 SARS-CoV-2 case numbers will increase again in the upcoming cold season, as previously observed
43 in late 2020². To date, there is however a lack of data examining the longevity of vaccination
44 responses, with the majority of published studies only providing follow-up data until three months
45 post-second dose³. Only two studies report data on extended time frames of six months after a
46 completed two-dose scheme^{4,5} and no studies considered follow-ups in patients receiving chronic
47 hemodialysis. Data on the actual impact of a third dose is equally scarce and so far limited to organ
48 transplant recipients, where a third dose significantly increased antibody responses⁶. In addition,
49 protection offered by first generation vaccines is reduced for SARS-CoV-2 variants of concern
50 (VoC)⁷, which now represent the majority of global infections⁸ making the decision if a third dose is
51 advisable even more critical for those with comorbidities, immunodeficiency’s or increased exposure
52 risk such as medical staff.

53 One risk group for SARS-CoV-2 infection and severe COVID-19 disease are hemodialysis patients,
54 with currently around 80,000 individuals requiring regular renal replacement therapy in Germany⁹.
55 Their various underlying medical conditions, comorbidities, and dialysis therapy often lead to a state
56 of generalized immunosuppression¹⁰. At the same time, they bear a continuous coronavirus exposure
57 risk due to the regular need for in-centre hemodialysis therapy, which prevents them from self-
58 isolating, or reducing contacts to avoid infection. Others and we have identified impaired cellular and
59 humoral responses not only following SARS-CoV-2 vaccination¹¹⁻¹³, but also towards other viruses
60 such as Influenza A or Hepatitis B¹⁰, however there is a lack of longitudinal vaccination response
61 studies against SARS-CoV-2 within this population. To guide future vaccination strategies if a third
62 dose for at-risk groups for severe COVID-19 is needed, we provide follow-up data in 76 individuals
63 receiving hemodialysis and 23 healthcare workers with no underlying conditions, for systemic and
64 mucosal B- and T-cell responses 16 weeks after full BNT162b2 vaccination and the neutralizing
65 potency of vaccination-induced antibodies. Due to the emergence of VoCs, which now constitute a
66 majority of global infections⁸ and on the basis that all currently licensed vaccines are formulated
67 against the original “wild-type (WT)” isolate (B.1), we also examined antibody binding and
68 neutralization towards the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.3) and Delta (B.1.617.2) VoCs.

69 As antibody levels are considered a proxy for protection, we initially examined the seroreversion rate
70 using MULTICOV-AB¹⁴, a previously published bead-based multiplex immunoassay that
71 simultaneously analyses over 20 different SARS-CoV-2 antigens including the receptor-binding
72 domains (RBDs) of VoCs and the endemic human coronaviruses. Similarly to our previous report¹¹,
73 anti-RBD IgG responses within the dialysis group (median normalized MFI=4.26, n=76) towards
74 SARS-CoV-2 WT RBD were significantly reduced compared to the control group (median normalized
75 MFI=13.6, n=23, $p<0.001$, **Fig. 1a**) 16 weeks after complete vaccination. Compared to three weeks
76 post-second dose (first time point), antibody titers significantly decreased by 61% in the control group
77 and 75% in the dialysis group ($p<0.001$, **Fig. 1a**). Anti-RBD IgG levels measured by MULTICOV-AB
78 were additionally verified with a commercial quantitative IVD antibody test (Spearman's rank 0.956,
79 **Extended Data Fig. 1a and b**). Whilst none of the samples of the control group were classified as
80 seronegative (titer below the cut-off) (**Extended Data Fig. 2**), 19.7% (15/76) of dialysis samples were
81 defined as such 16 weeks post-second dose, which constitutes a substantial increase from 3 weeks
82 post-second vaccination where only 5.3% (4/76) of samples were seronegative.

83 To evaluate whether this reduction in plasma anti-RBD IgG was also present at the mucosal site, we
84 profiled the local antibody response in saliva using MULTICOV-AB. As seen in plasma, there was a
85 significant reduction in saliva anti-RBD IgG titers in the dialysis (median=143, n=71) compared to the
86 control group (median=313.5, n=23, $p=0.02$, **Fig. 1b**). When comparing saliva anti-RBD IgG levels to
87 the initial time point, there was a statistically significant decline in both groups ($p<0.001$, **Fig. 1b**),
88 suggesting that they have potentially lost competence to prevent transmission if infected. When
89 examining anti-RBD IgA, there was a significant difference in titers between control and dialysis
90 individuals ($p=0.003$, **Extended Data Fig. 3a**), with 47.8% of control and 75% of dialysis individuals
91 classified as seronegative. This more pronounced reduction in IgA vs. IgG levels most likely
92 represents the shorter IgA half-life. Interestingly, saliva anti-RBD IgA tended to be higher in the
93 dialysis group although not significantly ($p=0.051$, **Extended Data Fig. 3b**).

94 We next examined whether neutralization potential was also hindered since there is solid evidence on
95 the protective role for neutralizing serum antibodies¹⁵. Using an ACE2-RBD competition assay, which
96 assesses neutralization potency towards SARS-CoV-2 wild-type (WT) and the currently circulating
97 Alpha, Beta, Gamma and Delta VoCs, we found that neutralization against WT SARS-CoV-2 RBD
98 was significantly reduced in the dialysis group compared to the controls ($p<0.001$, **Fig. 1c**) 16 weeks
99 after complete vaccination. 82.6% (19/23) of control and 89.5% (68/76, **Extended Data Fig. 2**) of
100 dialysis samples were below the 0.2 threshold, which indicates the absence of neutralizing activity.
101 This 0.2 neutralization threshold is based on information provided for other available ACE2
102 competition assays¹⁶. This is a substantial significant reduction (both $p<0.001$) in neutralizing activity
103 compared to 3 weeks post-second vaccination, where only 4.3% (1/23) of the control samples and
104 50.0% (38/76) of the dialysis samples were below the threshold (**Fig. 1c, Extended Data Fig. 2**).

105 As some individuals might be able to control and clear SARS-CoV-2 infections with a strong T-cell
106 response alone, we examined Spike-specific SARS-CoV-2 T-cell responses using a commercially
107 available Interferon γ release assay (IGRA). While absolute mean IFN γ responses in the dialysis
108 group compared to the control group tended to be lower (median 370 vs. 651 mIU/mL), this was non-
109 significant ($p=0.13$, **Fig. 1d**). Interestingly, within the control group, IFN γ release after restimulation
110 declined significantly from the first time point (median=1505, $p<0.001$, **Fig. 1d**), while for dialysis
111 patients, this decline was non-significant (median=580, $p=0.13$, **Fig. 1d**). This is likely due to the
112 majority of control samples being at the assay's upper limit of detection at the first time point, when
113 the dialysis samples already showed reduced IFN γ release. Overall, the number of non-responders
114 was higher in the hemodialysis group (40.8%, 31/76) than the control group (21.7%, 5/23, **Extended**
115 **Data Fig. 2**). A lack of serological response appears to be more driven by T-cell immunity than B-cell

116 immunity, with 2.6% (2/76) of the dialysis group having a T-cell response but no B-cell response, as
117 opposed to 23.6% (18/76) who had a B-cell response but no T-cell response. In total, 17.1% (13/76) of
118 the dialysis group were classified as complete non-responders due to the absence of both detectable
119 SARS-CoV-2 wild-type B- and T-cell responses, as opposed to none in the control group.

120 Having characterized response against wild-type SARS-CoV-2, we finally assessed humoral response
121 against the current VoCs (Alpha, Beta, Gamma and Delta). As shown with classical cell-culture based
122 virus neutralization assays⁷, neutralization responses were also reduced for all VoCs when compared
123 to WT using the previously described ACE2-RBD competition assay. Compared to the initial time
124 point, neutralization decreased significantly for both the Alpha and Beta VoCs (both $p < 0.001$, **Fig. 2a**
125 **and b**). We were unable to determine these changes for Gamma and Delta, since these variants were
126 not measured in the initial analysis. When comparing between the dialysis and the control cohort,
127 dialysis individuals had significantly reduced neutralization against Alpha ($p < 0.001$, **Fig. 2a**), Gamma
128 ($p = 0.014$, **Fig. 2c**) and Delta ($p = 0.002$, **Fig. 2c**), but not for Beta ($p = 0.08$, **Fig. 2b**). The number of
129 non-responders was variable between the different strains although consistently high, with 87.0% of
130 the control and 93.4% of dialysis considered non-responders against Alpha, 95.7% of control and
131 100% of dialysis against beta and Gamma, and 95.7% of control and 96.1% of dialysis against Delta.

132 As far as we are aware, this is the first study examining the longitudinal response following
133 vaccination, for more than 2 months post-vaccination within an immunocompromised population. In
134 comparison to other vaccine studies, which have mostly examined peak humoral response within one
135 month or alternative prime boost vaccination schedules with BNT162b2¹³, our data reveals a
136 substantial decrease in the following months in hemodialysis patients and healthy controls. Overall,
137 the decline in neutralizing anti-Spike RBD antibodies was comparable in both groups and the
138 difference between groups mostly driven by differences in the magnitude of the initial humoral
139 response. While this decrease is expected and can be attributed to the memory phase, the extent of the
140 reduction was unpredicted as it resulted in a significant proportion of individuals being classified as
141 seronegative. The reduction of salivary antibodies is particularly important as their presence has been
142 linked to reduced transmission potential¹⁷. This pattern of reduced antibody binding with increasing
143 time post vaccination was also reflected in diminishing neutralization potential. Worryingly, the
144 majority of individuals tested were classified below our defined neutralization threshold for WT RBD
145 with an almost complete non-responder rate against Delta, which is currently the dominant strain in
146 many parts of the world⁸. Although this does not automatically translate to a failure of vaccine
147 efficacy, as any active challenge of the immune system should result in expansion of memory B- and
148 T-cell populations along with increased (neutralizing) antibody titers, it does however suggest that
149 active protection against infection may be reduced. Whilst a recent study by Pfizer⁴ indicated that
150 BNT162b2 vaccine efficacy did only slightly decrease six months post-vaccination in the study cohort
151 (95% to 91%) in fully immunocompetent individuals, data from vaccinations in Israel identified a
152 reduction in efficacy to 40%¹⁸. In combination with our data, where 17.1% of the dialysis cohort were
153 classified as having no evidence for vaccine-elicited T- and B-cell immunity after four months, it is
154 suggestive that vaccine efficacy may be even further reduced within this patient group. For dialysis
155 patients, this is particularly concerning as they often suffer from comorbidities, which put them at
156 additional risk for severe COVID-19¹⁰. The lack of a considerable SARS-CoV-2 specific T-cell
157 response in dialysis patients may result from chronic inflammatory conditions leading to T-cell
158 exhaustion and suppression of IFN γ levels¹⁹. Differences in anti-SARS-CoV-2 T-cell kinetics between
159 groups presumably reflect difference in the magnitude of T-cell responses after boost and during the
160 contraction phase. To what extent T cell immunity contributes to protection from COVID-19 and
161 whether our IRGA results below a cut-off provide evidence for the lack of effective adaptive T-cell
162 immunity, requires further investigation.

163 This study is limited by the relatively small sample size of individuals, which were not age or gender
164 matched. However, the sample number and compromised matching is consistent with similar studies
165 on dialysis vaccine responses¹³. While studies have indicated that differences exist in both protection
166 and antibody responses²⁰ after different COVID-19 vaccination schedules, our study of Pfizer's
167 BNT162b represents a real-world situation for the majority of dialysis patients. Considering reduced
168 anti-Spike responses four weeks post-vaccination in patients with other chronic conditions⁶, these
169 groups should undergo careful monitoring to determine whether their responses also decrease
170 substantially over time. Taken together, our results strongly argue towards administering a third dose
171 of BNT162b2 preferentially to all individuals undergoing chronic hemodialysis.

172

173 **References**

- 174 1. European Centre for Disease Control and Prevention: Overview of the implementation of
175 COVID-19 vaccination strategies and deployment plans in the EU/EEA
176 ([https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-](https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans)
177 [vaccination-strategies-and-deployment-plans](https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans)). (2021).
178 2. Robert Koch Institut: COVID-19-Dashboard
179 (<https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4>).
180 3. Ibarondo, F.J., *et al.* Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody
181 Responses. *ACS Nano* **15**, 11180-11191 (2021).
182 4. Thomas, S.J., *et al.* Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19
183 Vaccine. *medRxiv*, 2021.2007.2028.21261159 (2021).
184 5. Doria-Rose, N., *et al.* Antibody Persistence through 6 Months after the Second Dose of
185 mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine* **384**, 2259-2261
186 (2021).
187 6. Kamar, N., *et al.* Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant
188 Recipients. *New England Journal of Medicine* **385**, 661-662 (2021).
189 7. Altmann, D.M., Boyton, R.J. & Beale, R. Immunity to SARS-CoV-2 variants of concern.
190 *Science* **371**, 1103 (2021).
191 8. CoVariants (<https://covariants.org/>)
192 9. Girndt, M., Trocchi, P., Scheidt-Nave, C., Markau, S. & Stang, A. The Prevalence of Renal
193 Failure. *Dtsch Arztebl International* **113**, 85-91 (2016).
194 10. Windpessl, M., *et al.* COVID-19 vaccines and kidney disease. *Nat Rev Nephrol* **17**, 291-293
195 (2021).
196 11. Strengert, M., *et al.* Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine
197 in patients on haemodialysis. *EBioMedicine* **70**, 103524 (2021).
198 12. Schrezenmeier, E., *et al.* Immunogenicity of COVID-19 Tozinameran Vaccination in Patients
199 on Chronic Dialysis. *Frontiers in Immunology* **12**, 2550 (2021).
200 13. Carr, E.J., *et al.* Neutralising antibodies after COVID-19 vaccination in UK haemodialysis
201 patients. *The Lancet* (2021).
202 14. Becker, M., *et al.* Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-
203 Ab to evaluate endemic coronavirus cross-reactivity. *Nat Commun* **12**, 1152 (2021).
204 15. Khoury, D.S., *et al.* Neutralizing antibody levels are highly predictive of immune protection
205 from symptomatic SARS-CoV-2 infection. *Nat Med* (2021).
206 16. Lopez, E., *et al.* Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD
207 variants with a novel competitive multiplex assay. *medRxiv*, 2021.2003.2020.21254037
208 (2021).
209 17. Becker, M., *et al.* Immune response to SARS-CoV-2 variants of concern in vaccinated
210 individuals. *Nature Communications* **12**, 3109 (2021).
211 18. [https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-](https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf)
212 [committee/he/files_publications_corona_two-dose-vaccination-data.pdf](https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf).
213 19. Hartzell, S., *et al.* Kidney Failure Associates With T Cell Exhaustion and Imbalanced
214 Follicular Helper T Cells. **11**(2020).
215 20. Garcia, P., *et al.* COVID19 vaccine type and humoral immune response in patients receiving
216 dialysis. *medRxiv*, 2021.2008.2002.21261516 (2021).

217

218

219 **Author Contributions**

220 MS, GK, GMNB and NSM conceived the study. AD, MS, MB, DJ, NSM, A D-J, and GMNB
221 designed the experiments. GMR, MVS, and JG performed the experiments. KL, AB, EW, GL, AC, A
222 D-J, MVS, ADJ and GMNB collected samples and data or organized their collection. PDK, BT and
223 UR produced and designed recombinant assay proteins. AD, MS, MB and JG performed data
224 collection and analysis. AD and MB generated the figures. AD and MS wrote the manuscript. All
225 authors critically reviewed and approved the final manuscript.

226

227 **Funding**

228

229 This work was funded by the Initiative and Networking Fund of the Helmholtz Association of German
230 Research Centers, EU Horizon 2020 research and innovation program and the State Ministry of
231 Baden-Wuerttemberg for Economic Affairs, Labour and Tourism.

232

233 **Competing interest**

234 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute
235 at the University of Tübingen is involved in applied research projects as a fee for services with the
236 Luminex Corporation. The other authors declare no competing interest.

237

238 **Acknowledgments**


239 We thank staff and participants at the Dialysis Centre Eickenhof for their continued support to make
240 this study possible.

241

242

243

244



245


246 **Fig. 1 | Humoral and cellular responses induced by BNT162b2 against SARS-CoV-2 significantly decrease**
 247 **from 3 weeks to 16 weeks post-second vaccination.**

248 IgG response in plasma (a), IgG response in saliva (b), neutralizing capacity towards SARS-CoV-2 WT B.1 (c)
 249 and T-cell response measured by IGRA (d) between dialysis (blue, n=76) and control (red, n=23) groups. Samples
 250 were taken at two time points following vaccination with Pfizer BNT162b2: T1 (three weeks post-second dose)
 251 and T2 (16 weeks post-second dose). Saliva (b) has reduced sample numbers in both groups due to issues in
 252 sample collection (T1 control n=22, T1 dialysis n=69, T2 control n=23, T2 dialysis=71). T1 time point data has
 253 already been published¹¹ and is reproduced here for clarity. Boxes represent the median, 25th and 75th percentiles,
 254 whiskers show the largest and smallest non-outlier values. Outliers were determined by 1.5 IQR. Statistical
 255 significance was calculated by Wilcoxon matched-pairs signed rank test when comparing between T1 and T2,
 256 and two-sided Mann-Whitney-U test when comparing between control and dialysis. Significance is defined as
 257 *** p<0.001, ** p<0.01, * p<0.05 and ns p>0.05.

258

259

260



261

262 **Fig. 2 | Dialysis patients have reduced neutralizing capacity against SARS-CoV-2 VOCs.**

263 Neutralizing capacity of plasma IgG towards SARS-CoV-2 VoCs Alpha (a), Beta (b), Gamma and Delta (both c)
264 in the control (red, n=23) and dialysis groups (blue, n=76) 16 weeks post-second vaccination with Pfizer
265 BNT162b2. Neutralization capacity is displayed as ratio where 1 indicates maximum neutralization and 0
266 no neutralization. Boxes represent the median, 25th and 75th percentiles, whiskers show the largest and smallest non-

267 outlier values. Outliers were determined by 1.5 IQR. Statistical significance was calculated by two-sided Mann-
268 Whitney-U test. Statistical significance is defined as *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$ and ns $p > 0.05$.

269

270